Health insurers score major win with higher 2027 Medicare Advantage rates
The stocks of major Medicare Advantage insurers surged on the announcement.
Editorial Staff Apr 7
Health
Latest Health stories from Life.
Capping Insulin Costs at $35 May Improve Treatment Adherence for Type 2 Diabetes
A recent study suggests that limiting insulin prices to $35 per month could enhance adherence to treatment among individuals with type 2 diabetes, highlighting the potential impact of cost on health outcomes.
Editorial Staff Apr 7
Gilead Acquires Tubulis for Over $3 Billion to Boost Oncology Portfolio
In a significant move to enhance its oncology pipeline, Gilead has announced the acquisition of Tubulis, a German biotech firm, for more than $3 billion.
Editorial Staff Apr 7
Merck's HIV Prevention Pill: A Cost-Effective Solution Awaiting Generic Production
With estimates suggesting Merck's experimental HIV prevention pill could cost under $5 annually, researchers are calling for the company to allow generic production.
Editorial Staff Apr 7
A star scientist showed that better genetics lessons could reduce racism. It was the death knell for his career
Strategic angle: Brian Donovan had persuaded high school teachers and education researchers that prejudice might be ended by changing how genetics is taught.
Editorial Staff Apr 7
FDA backs proposals to entice pharma companies to test, make drugs domestically
Strategic angle: From tariffs to incentives, the administration wants to push companies to manufacture drugs in the U.S.
Editorial Staff Apr 7
Opinion: How the insurance system quietly undoes recovery from addiction
Strategic angle: People who have been stable for years are suddenly re-exposed to risk — not because their disease worsened, but because their coverage did.
Editorial Staff Apr 7
Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI
Strategic angle: “Health care will become autonomous because the survival of health systems depends upon it,” writes former Geisinger CEO Glenn Steele.
Editorial Staff Apr 7
Research Revealing How the Brain Flushes Waste Named STAT Madness Editors’ Pick
Strategic angle: For researcher Maiken Nedergaard, ‘diseases of aging are basically all about dirty brains’
Editorial Staff Apr 7
University of Michigan wins 2026 STAT Madness for new insights into abdominal aortic aneurysms
Strategic angle: The researchers identified a driving force behind the condition, opening up a potential target for new therapies.
Editorial Staff Apr 7
Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits
Strategic angle: A bill is moving through the Colorado legislature that would exempt orphan drugs from pricing caps that might be pursued by the state.
Editorial Staff Apr 6
Global Health Funding in the FY 2027 President’s Budget Request
Strategic angle: This budget summary provides an analysis of global health funding amounts provided in the President's FY 2027 budget request.
Editorial Staff Apr 6
California's Medicaid Work Requirements Amid Budget Shortfalls
Strategic angle: Examining the state's plans to implement work requirements in Medicaid while facing significant budget challenges.
Editorial Staff Apr 6
STAT+: A key Medicare Advantage announcement is due today
Strategic angle: Today's announcement will set the tone for how the Trump administration wants to work with private Medicare insurers.
Editorial Staff Apr 6
How a four-month FDA delay forced a small biotech company to close its doors
A small biotech company faced a critical setback due to a delayed agreement with the FDA, leading to its closure.
Editorial Staff Apr 6
Stealth biotech Stipple bets on secretive ADCs
Strategic angle: How thin science fuels peptide hype, blowback to proposed NIH cuts, and more biotech news from The Readout
Editorial Staff Apr 6
UnitedHealth makes a bet on AI. What does it mean for us?
Strategic angle: A hep B trial raises ethical questions, the peptide hype, and more Morning Rounds news
Editorial Staff Apr 6
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.
Editorial Staff Apr 6
Opinion: ‘Medical nutrition’ helps keep my son, and many others, healthy. But insurance won’t cover it
Strategic angle: Lifelong disorders require lifelong treatments.
Editorial Staff Apr 6
Opinion: When my child is in psychosis, the pediatric health care system can’t help us
Strategic angle: “There is no off switch when the crisis is your child,” writes Liz Koch.
Editorial Staff Apr 6